NCT01182207View on ClinicalTrials.gov

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions
Healthy
Interventions
DRUG

Drospirenone/Ethinyl Estradiol (Gianvi®)

3 mg/0.02 mg Tablets

DRUG

YAZ®

3 mg/0.02 mg Tablets

Trial Locations (1)

58104

PRACS Institute, Ltd., Fargo

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT01182207 - Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions | Biotech Hunter | Biotech Hunter